BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Banales JM, Iñarrairaegui M, Arbelaiz A, Milkiewicz P, Muntané J, Muñoz-Bellvis L, La Casta A, Gonzalez LM, Arretxe E, Alonso C, Martínez-Arranz I, Lapitz A, Santos-Laso A, Avila MA, Martínez-Chantar ML, Bujanda L, Marin JJG, Sangro B, Macias RIR. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology 2019;70:547-62. [PMID: 30325540 DOI: 10.1002/hep.30319] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Herraez E, Romero MR, Macias RIR, Monte MJ, Marin JJG. Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2020;9:211-214. [PMID: 32355682 DOI: 10.21037/hbsn.2019.10.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World J Gastrointest Oncol 2021;13:332-50. [PMID: 34040697 DOI: 10.4251/wjgo.v13.i5.332] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
3 Lang SA, Bednarsch J, Joechle K, Amygdalos I, Czigany Z, Heij L, Ulmer TF, Neumann UP. Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art. Expert Rev Gastroenterol Hepatol 2021;15:497-510. [PMID: 33970740 DOI: 10.1080/17474124.2021.1912591] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Feng N, Yu F, Yu F, Feng Y, Zhu X, Xie Z, Zhai Y. Metabolomic biomarkers for hepatocellular carcinoma: A systematic review. Medicine (Baltimore) 2022;101:e28510. [PMID: 35060504 DOI: 10.1097/MD.0000000000028510] [Reference Citation Analysis]
5 Nault JC, Villanueva A. Biomarkers for Hepatobiliary Cancers. Hepatology. 2021;73 Suppl 1:115-127. [PMID: 32045030 DOI: 10.1002/hep.31175] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
6 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
7 Zhu N, Huang S, Zhang Q, Zhao Z, Qu H, Ning M, Leng Y, Liu J. Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl4-Induced NASH Mice and the Effect of Obeticholic Acid. Metabolites 2021;11:374. [PMID: 34200685 DOI: 10.3390/metabo11060374] [Reference Citation Analysis]
8 Li S, Weng J, Song F, Li L, Xiao C, Yang W, Xu J. Circular RNA circZNF566 promotes hepatocellular carcinoma progression by sponging miR-4738-3p and regulating TDO2 expression. Cell Death Dis 2020;11:452. [PMID: 32532962 DOI: 10.1038/s41419-020-2616-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
9 Wang PP, Song X, Zhao XK, Wei MX, Gao SG, Zhou FY, Han XN, Xu RH, Wang R, Fan ZM, Ren JL, Li XM, Wang XZ, Yang MM, Hu JF, Zhong K, Lei LL, Li LY, Chen Y, Chen YJ, Ji JJ, Yang YZ, Li J, Wang LD. Serum Metabolomic Profiling Reveals Biomarkers for Early Detection and Prognosis of Esophageal Squamous Cell Carcinoma. Front Oncol 2022;12:790933. [DOI: 10.3389/fonc.2022.790933] [Reference Citation Analysis]
10 Li Y, Xue H, Fang S, Wang G, Wang Y, Wang T, Shi R, Wu J, Ma Y. Time-series metabolomics insights into the progressive characteristics of 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced cholestatic liver fibrosis in mice. J Pharm Biomed Anal 2021;198:113986. [PMID: 33690095 DOI: 10.1016/j.jpba.2021.113986] [Reference Citation Analysis]
11 Xu Q, Huang S, Xu ZM, Ji K, Zhang X, Xu WP, Wei W. Promotion effects of DEHP on hepatocellular carcinoma models: up-regulation of PD-L1 by activating the JAK2/STAT3 pathway. Toxicol Res (Camb) 2021;10:376-88. [PMID: 34141151 DOI: 10.1093/toxres/tfab018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100479] [Reference Citation Analysis]
13 Bai C, Wang H, Dong D, Li T, Yu Z, Guo J, Zhou W, Li D, Yan R, Wang L, Wang Z, Li Y, Ren L. Urea as a By-Product of Ammonia Metabolism Can Be a Potential Serum Biomarker of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:650748. [PMID: 33869206 DOI: 10.3389/fcell.2021.650748] [Reference Citation Analysis]
14 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Reference Citation Analysis]
15 Yang K, Jia M, Cheddah S, Zhang Z, Wang W, Li X, Wang Y, Yan C. Peptide ligand-SiO2 microspheres with specific affinity for phosphatidylserine as a new strategy to isolate exosomes and application in proteomics to differentiate hepatic cancer. Bioactive Materials 2021. [DOI: 10.1016/j.bioactmat.2021.12.017] [Reference Citation Analysis]
16 Fung BM, Tabibian JH. Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices. Expert Rev Gastroenterol Hepatol 2021;15:487-96. [PMID: 33682586 DOI: 10.1080/17474124.2021.1900732] [Reference Citation Analysis]
17 Pezzuto F, Izzo F, De Luca P, Biffali E, Buonaguro L, Tatangelo F, Buonaguro FM, Tornesello ML. Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3771. [PMID: 34359670 DOI: 10.3390/cancers13153771] [Reference Citation Analysis]
18 Sheng LQ, Li JR, Qin H, Liu L, Zhang DD, Zhang Q, Huang ML, Li XL, Xu XY, Wei YN, Chen ZS, Luo H, Zhang JY, Zhou CH, Chen H, Chen ZG, Li FG, Li NF. Blood exosomal micro ribonucleic acid profiling reveals the complexity of hepatocellular carcinoma and identifies potential biomarkers for differential diagnosis. World J Gastrointest Oncol 2020; 12(10): 1195-1208 [PMID: 33133386 DOI: 10.4251/wjgo.v12.i10.1195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Méndez-Blanco C, Fernández-Palanca P, Fondevila F, González-Gallego J, Mauriz JL. Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: a systematic review with meta-analysis. Ther Adv Med Oncol 2021;13:1758835920987071. [PMID: 33613697 DOI: 10.1177/1758835920987071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Kang X, Bai L, Qi X, Wang J. Screening and identification of key genes between liver hepatocellular carcinoma (LIHC) and cholangiocarcinoma (CHOL) by bioinformatic analysis. Medicine (Baltimore) 2020;99:e23563. [PMID: 33327311 DOI: 10.1097/MD.0000000000023563] [Reference Citation Analysis]
21 Chen F, Wang J, Wu Y, Gao Q, Zhang S. Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy. Front Oncol 2022;12:822449. [DOI: 10.3389/fonc.2022.822449] [Reference Citation Analysis]
22 Si Y, Wang X, Pan C, Wang Y, Lu Z. An Efficient Nomogram for Discriminating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma: A Retrospective Study. Front Oncol 2022;12:833999. [DOI: 10.3389/fonc.2022.833999] [Reference Citation Analysis]
23 Fung BM, Tabibian JH. Cholangiocarcinoma in patients with primary sclerosing cholangitis.Curr Opin Gastroenterol. 2020;36:77-84. [PMID: 31850928 DOI: 10.1097/MOG.0000000000000616] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
24 Asimakopoulou A, Vucur M, Luedde T, Schneiders S, Kalampoka S, Weiss TS, Weiskirchen R. Perilipin 5 and Lipocalin 2 Expression in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E385. [PMID: 30893876 DOI: 10.3390/cancers11030385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
25 Xu F, Li H, Pan Y, Zeng Y, Li J, Li S. Effects of Ganfule capsule on microbial and metabolic profiles in anti-hepatocellular carcinoma. J Appl Microbiol 2021. [PMID: 34564943 DOI: 10.1111/jam.15307] [Reference Citation Analysis]
26 Li S, Li L, Wu J, Song F, Qin Z, Hou L, Xiao C, Weng J, Qin X, Xu J. TDO Promotes Hepatocellular Carcinoma Progression. Onco Targets Ther 2020;13:5845-55. [PMID: 32606795 DOI: 10.2147/OTT.S252929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Yu S, Liu C, Hou Y, Li J, Guo Z, Chen X, Zhang L, Peng S, Hong S, Xu L, Li X, Liu R, Chen S, Li B, Weng Z, Li Y, Lv W, Yu J, Xiao H. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer. Oncogene. [DOI: 10.1038/s41388-022-02254-5] [Reference Citation Analysis]
28 Saito R, Yoshimura K, Shoda K, Furuya S, Akaike H, Kawaguchi Y, Murata T, Ogata K, Iwano T, Takeda S, Ichikawa D. Diagnostic significance of plasma lipid markers and machine learning-based algorithm for gastric cancer. Oncol Lett 2021;21:405. [PMID: 33841566 DOI: 10.3892/ol.2021.12666] [Reference Citation Analysis]
29 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Lan Y, Zhu W, Duan X, Deng T, Li S, Liu Y, Yang Z, Wen Y, Luo L, Zhao S, Wang J, Zhao Z, Wu W, Zeng G. Glycine suppresses kidney calcium oxalate crystal depositions via regulating urinary excretions of oxalate and citrate. J Cell Physiol 2021;236:6824-35. [PMID: 33772775 DOI: 10.1002/jcp.30370] [Reference Citation Analysis]
31 A. Sherif Z. The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. In: Hamdy Gad E, editor. Nonalcoholic Fatty Liver Disease - An Update. IntechOpen; 2019. [DOI: 10.5772/intechopen.85780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol 2019;16:748-66. [PMID: 31666728 DOI: 10.1038/s41575-019-0217-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
33 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 80.0] [Reference Citation Analysis]
34 Macias RIR, Muñoz-Bellvís L, Sánchez-Martín A, Arretxe E, Martínez-Arranz I, Lapitz A, Gutiérrez ML, La Casta A, Alonso C, González LM, Avila MA, Martinez-Chantar ML, Castro RE, Bujanda L, Banales JM, Marin JJG. A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1433. [PMID: 32486461 DOI: 10.3390/cancers12061433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
35 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Shi Z, Qu X, Guo C, Zhang L, Peng C, Xie Z, Hua K, Qiu J. Identification of clinical trait-related small RNA biomarkers with weighted gene co-expression network analysis for personalized medicine in endocervical adenocarcinoma. Aging (Albany NY) 2021;13:22361-74. [PMID: 34542422 DOI: 10.18632/aging.203543] [Reference Citation Analysis]
37 Ren S, Li Q, Liu S, Qi Q, Duan S, Mao B, Li X, Wu Y, Zhang L. Clinical Value of Machine Learning-Based Ultrasomics in Preoperative Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Multicenter Study. Front Oncol 2021;11:749137. [PMID: 34804935 DOI: 10.3389/fonc.2021.749137] [Reference Citation Analysis]
38 Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic Reprogramming in Cholangiocarcinoma. J Hepatol 2022:S0168-8278(22)00314-2. [PMID: 35594992 DOI: 10.1016/j.jhep.2022.04.038] [Reference Citation Analysis]
39 Urban SK, Sänger H, Krawczyk M, Julich-Haertel H, Willms A, Ligocka J, Azkargorta M, Mocan T, Kahlert C, Kruk B, Jankowski K, Patkowski W, Krawczyk M, Zieniewicz K, Hołówko W, Krupa Ł, Rzucidło M, Gutkowski K, Wystrychowski W, Król R, Raszeja-Wyszomirska J, Słomka A, Schwab R, Wöhler A, Gonzalez-Carmona MA, Gehlert S, Sparchez Z, Banales JM, Strassburg CP, Lammert F, Milkiewicz P, Kornek M. Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. Liver Int 2020;40:3103-16. [PMID: 32614460 DOI: 10.1111/liv.14585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
40 Grimsrud MM, Folseraas T. Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis. Liver Int 2019;39:2230-7. [PMID: 31216595 DOI: 10.1111/liv.14180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
41 Vedeld HM, Folseraas T, Lind GE. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis - The promise of DNA methylation and molecular biomarkers.JHEP Rep. 2020;2:100143. [PMID: 32939446 DOI: 10.1016/j.jhepr.2020.100143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Curran A, Rull A, Navarro J, Vidal-González J, Martin-Castillo M, Burgos J, Falcó V, Ribera E, Torrella A, Planas B, Peraire J, Crespo M. Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. J Clin Med 2020;9:E1246. [PMID: 32344934 DOI: 10.3390/jcm9051246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Song J, Li Y, Bowlus CL, Yang G, Leung PSC, Gershwin ME. Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. Clin Rev Allergy Immunol. 2020;58:134-149. [PMID: 31463807 DOI: 10.1007/s12016-019-08764-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
44 Chang YC, Chen MH, Yeh CN, Hsiao M. Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. Biomolecules 2020;10:E1377. [PMID: 32998289 DOI: 10.3390/biom10101377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Mocan LP, Ilieș M, Melincovici CS, Spârchez M, Crăciun R, Nenu I, Horhat A, Tefas C, Spârchez Z, Iuga CA, Mocan T, Mihu CM. Novel approaches in search for biomarkers of cholangiocarcinoma. World J Gastroenterol 2022; 28(15): 1508-1525 [DOI: 10.3748/wjg.v28.i15.1508] [Reference Citation Analysis]
46 Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs 2021;30:377-88. [PMID: 33622120 DOI: 10.1080/13543784.2021.1880564] [Reference Citation Analysis]
47 Lee SE, Shin HE, Lee MR, Kim YH, Cho SH, Ju JW. Risk Factors of Clonorchis sinensis Human Infections in Endemic Areas, Haman-Gun, Republic of Korea: A Case-Control Study. Korean J Parasitol. 2020;58:647-652. [PMID: 33412768 DOI: 10.3347/kjp.2020.58.6.647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919848184. [PMID: 31205505 DOI: 10.1177/1758835919848184] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
49 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, Braconi C, Frampton AE, Bridgewater J, Overi D, Pereira SP, Rengo M, Kather JN, Lamarca A, Pedica F, Forner A, Valle JW, Gaudio E, Alvaro D, Banales JM, Carpino G. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 2022:gutjnl-2022-327099. [PMID: 35580963 DOI: 10.1136/gutjnl-2022-327099] [Reference Citation Analysis]
51 Lu L, Li H, Wu X, Rao J, Zhou J, Fan S, Shen Q. HJC0152 suppresses human non-small-cell lung cancer by inhibiting STAT3 and modulating metabolism. Cell Prolif 2020;53:e12777. [PMID: 32022328 DOI: 10.1111/cpr.12777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
52 Cao L, Han Y, Wang Y, Pei L, Yue Z, Qin L, Liu B, Cui J, Jia M, Wang H. Metabolic Profiling Identified a Novel Biomarker Panel for Metabolic Syndrome-Positive Hepatocellular Cancer. Front Endocrinol 2022;12:816748. [DOI: 10.3389/fendo.2021.816748] [Reference Citation Analysis]
53 Fu J, Zhang Y, Liu J, Lian X, Tang J, Zhu F. Pharmacometabonomics: data processing and statistical analysis. Brief Bioinform 2021:bbab138. [PMID: 33866355 DOI: 10.1093/bib/bbab138] [Reference Citation Analysis]
54 Rodrigues PM, Vogel A, Arrese M, Balderramo DC, Valle JW, Banales JM. Next-Generation Biomarkers for Cholangiocarcinoma. Cancers (Basel) 2021;13:3222. [PMID: 34203269 DOI: 10.3390/cancers13133222] [Reference Citation Analysis]
55 Urman JM, Herranz JM, Uriarte I, Rullán M, Oyón D, González B, Fernandez-Urién I, Carrascosa J, Bolado F, Zabalza L, Arechederra M, Alvarez-Sola G, Colyn L, Latasa MU, Puchades-Carrasco L, Pineda-Lucena A, Iraburu MJ, Iruarrizaga-Lejarreta M, Alonso C, Sangro B, Purroy A, Gil I, Carmona L, Cubero FJ, Martínez-Chantar ML, Banales JM, Romero MR, Macias RIR, Monte MJ, Marín JJG, Vila JJ, Corrales FJ, Berasain C, Fernández-Barrena MG, Avila MA. Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Cancers (Basel) 2020;12:E1644. [PMID: 32575903 DOI: 10.3390/cancers12061644] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]